Multiple System Atrophy - Global Strategic Business Report

The global market for Multiple System Atrophy was estimated at US$145.2 Million in 2024 and is projected to reach US$163.5 Million by 2030, growing at a CAGR of 2.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Multiple System Atrophy market.

Global Multiple System Atrophy Market - Key Trends & Drivers Summarized

Why Is Multiple System Atrophy a Focus Area in Neurodegenerative Disease Research?

Multiple System Atrophy (MSA) is a rare and progressive neurodegenerative disorder that affects multiple regions of the central nervous system, leading to a combination of movement, autonomic, and cerebellar symptoms. The disease shares features with Parkinson's disease but progresses more rapidly and lacks sustained response to dopaminergic therapy. Diagnosis is clinically challenging due to symptom overlap with other movement disorders, often resulting in delayed intervention. This complexity has placed MSA under increased clinical and research attention, particularly as early and accurate diagnosis is critical for care planning and trial enrollment.

The condition is categorized into two subtypes: MSA-P (parkinsonian) and MSA-C (cerebellar), depending on the predominant symptom profile. Both forms involve widespread alpha-synuclein accumulation in glial cells, distinguishing MSA pathologically from Parkinson's and other related disorders. Management is currently symptomatic, focusing on improving quality of life through pharmacological and supportive therapies, as no curative treatment exists. This unmet need continues to drive new approaches in diagnostics, disease-modifying therapies, and multidisciplinary care frameworks.

What Therapeutic Strategies Are Being Explored to Address MSA?

Current treatment strategies remain palliative, aimed at managing motor symptoms with dopaminergic agents and addressing autonomic dysfunction with medications that stabilize blood pressure, bladder function, and sleep disturbances. However, limited and short-lived responses highlight the urgent need for disease-modifying options. Several research programs are now investigating approaches that target alpha-synuclein aggregation, neuroinflammation, and mitochondrial dysfunction, which are believed to underlie disease progression.

Clinical trials are evaluating small molecules, monoclonal antibodies, and gene therapies that intervene in neurodegenerative pathways. Some investigational drugs aim to slow glial cell damage or modulate immune system activity within the brain. Interest is also growing in regenerative strategies, including stem cell-based therapies, though these remain at early research stages. As research continues, patient registries, biomarker identification, and improved imaging tools are playing a key role in refining study designs and enabling earlier intervention.

Which Healthcare Systems and Patient Needs Influence Market Dynamics?

Due to its rarity, MSA is typically managed at specialized neurology centers that offer coordinated care from movement disorder specialists, autonomic experts, and rehabilitative professionals. The condition places a high burden on caregivers and healthcare systems due to its rapid progression and multi-system involvement. Patients often require a combination of pharmacological support, physical therapy, speech therapy, and assistive technologies. Early access to multidisciplinary care and patient education can delay complications and improve day-to-day functioning.

Public awareness remains low, leading to underdiagnosis and inconsistent care pathways across different regions. Advocacy organizations are working to expand education, patient support, and clinical trial participation. Diagnostic uncertainty continues to hinder access to targeted treatments and appropriate referrals. Increasing awareness among primary care physicians and neurologists is essential to improve early detection and reduce misdiagnosis rates, which currently remain high for MSA.

Growth in the Multiple System Atrophy Market Is Driven by Several Factors

Growth in the multiple system atrophy market is driven by several factors. Rising diagnostic capabilities and neuroimaging tools are improving identification and subtyping of patients. Increased research investment in rare neurodegenerative diseases is leading to more clinical trials targeting underlying disease mechanisms. Expansion of patient advocacy networks supports awareness, education, and trial recruitment. Advances in biomarker research and imaging methods facilitate earlier diagnosis and intervention. Broader access to multidisciplinary care models and symptom management strategies improves long-term patient outcomes. Lastly, regulatory interest in supporting orphan drug development accelerates innovation and investment in this challenging and underserved disease area.

Scope Of Study:

The report analyzes the Multiple System Atrophy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Diagnosis Type (Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Tilt Table Test, Other Diagnosis Types); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Magnetic Resonance Imaging segment, which is expected to reach US$67.3 Million by 2030 with a CAGR of a 2.7%. The Positron Emission Tomography segment is also set to grow at 1.0% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $39.6 Million in 2024, and China, forecasted to grow at an impressive 4.1% CAGR to reach $31.0 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Multiple System Atrophy Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Multiple System Atrophy Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Multiple System Atrophy Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as AC Immune, Alterity Therapeutics, Asklepios BioPharmaceutical (AskBio), AstraZeneca plc, Biohaven Pharmaceuticals and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 36 companies featured in this Multiple System Atrophy market report include:

• AC Immune
• Alterity Therapeutics
• Asklepios BioPharmaceutical (AskBio)
• AstraZeneca plc
• Biohaven Pharmaceuticals
• Biogen Idec
• Brain Neurotherapy Bio, Inc.
• Corestem, Inc.
• H. Lundbeck A/S
• Inhibikase Therapeutics
• Ionis Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Modag GmbH
• Neuramedy
• ProMIS Neurosciences Inc.
• Retrotpe
• Sanofi S.A.
• Stealth BioTherapeutics Corp.
• Theravance Biopharma, Inc.
• Teva Pharmaceutical Industries Ltd.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.